Being approved by FDA on 6th of December 2013, Sofosbuvir treatment is the latest and most advanced chronic Hepatitis C treatment. The drug that contains Sofosbuvir named Sovaldi and developed by Gilead Sciences was one of the most anticipated, if not the most anticipated drug in 2013. In 2014 it is already bound to change the way we treat Hepatitis C because of Sovaldi's key advantages.
There are two different treatments with Sofosbuvir. The most important change came for genotype 2 and genotype 3 Hepatitis C, where Sofosbuvir is used as a dual regiment together with ribavirin, antiviral drug that is also used in interferon treatment. The advantages of Sofosbuvir treatment are outstanding:
1. First all-oral treatment. With interferon, patients had to administrate intracutaneous injection, which is both painful for the patient and impractical. In Sofosbuvir treatment a patient needs only to take a pill of Sovaldi (trade name for Sofosbuvir) with little water and that's it.
2. Faster treatment. Hepatitis C treatment with Sofosbuvir takes 12 weeks for genotypes 1, 2 and 4 Hep C. For genotype 3 it takes 24 weeks. This is a great reduction in therapy duration from 24-48 week previous treatment with interferon.
3. No known resistance. The problem with antibiotic and antiviral medicines that have been around for long enough is that the bacteria and viruses learn how to fight them. In the case of Hep C treatment, this is starting to show for interferon, which doesn't work as well as before. However, Sofosbuvir treatment is only beginning and the Hep C virus is not ready for it – therefore there is no resistance against Sofosbuvir. It was also shown that patients that underwent interferon treatment without getting better were helped by Sofosbuvir treatment.
4. No interferon side effects. The previous problem with Hep C treatment with interferon was that interferon produces flu-like side effects. This is natural and expected from interferon, but unwanted in Hep C therapy. Sofosbuvir, on the other side, has no such side effects because Sofosbuvir treatment doesn't use interferon.
The most important thing, however, is the cure rate. The cure rate numbers for interferon are more than 75% for genotype 2 and 3 patients, and less than 50% for most common genotype 1.
Cure rate with Sofosbuvir treatment is an outstanding 89% to 95% for genotype 2, according to the clinical studies. For genotype 3 the cure rate is 61% to 63%. But what makes Sofosbuvir or Sovaldi drug the champion is the cure rate for the most common genotype 1 Hep C – genotype 1 is predominant Hep C with about 70% of all Hep C patients.
89%! This is the cure rate for the most important Hepatitis C genotype, up from less than 50% cure rate with previous interferon treatment.
At the advisory committee hearing, Gilead scientists reported sustained viral clearance at 12 weeks (SVR12) ranging from 89% to 95% for genotype 2 and 61% to 63% for genotype 3. For HCV genotype 1, which accounts for about 70% of all HCV in the United States, sofosbuvir-based triple therapy including pegIFN produced an SVR12 of 89%.
“I think the move away from interferon and toward a high probability of success is remarkably encouraging for all of us…. Suddenly, it's realistic to think we can cure most patients with hepatitis C,” Greg Fitz, MD, president of the American Association for the Study of Liver Diseases.
This is what was the response from one of the leading professionals and experts in not only Hepatitis C, but all liver diseases, according to this Sofosbuvir treatment article.
It is worth mentioning that for Hepatitis C genotype 1 there is a three-drug treatment that includes interferon, ribavirin and Sofosbuvir. The treatment is as such highly successful and with reduced duration, but the addition of interferon in the therapy causes the same side effects and the problem of drug resistance. Also needles have to be used to administer interferon. Nonetheless, the bottom line is that the treatment with the addition of Sofosbuvir is curing Hep C genotype 1 patients like nothing else.
Thanks to Gilead Sciences, the Sovaldi drug containing Sofosbuvir is accessible on the market.
This site is about bring the knowledge of Sofosbuvir treatment and Sofosbuvir itself closed to people. More about the wonder molecule itself, the mechanism of action, Sovaldi drug development and Sovaldi drug costs can be found is Sofosbuvir section.